• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Ensysce Biosciences Inc. (Amendment)

    2/14/24 4:31:06 PM ET
    $ENSC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENSC alert in real time by email
    SC 13G/A 1 tm246286d4_sc13ga.htm SCHEDULE 13G/A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    ENSYSCE BIOSCIENCES, INC.
    (Name of Issuer)
     
    COMMON STOCK, $0.0001 PAR VALUE PER SHARE
    (Title of Class of Securities)
     
    293602207
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1(b)
      x Rule 13d-1(c)
      ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Page 1 of 13 Pages)

     

     

     

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 293602207 Page 2 of 13

     

    1

    NAMES OF REPORTING PERSONS

     

    Lincoln Park Capital Fund, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Illinois



    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    124,008

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    124,008

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    124,008

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.792%

    12

    TYPE OF REPORTING PERSON

     

    OO

     

     

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 293602207 Page 3 of 13

     

    1

    NAMES OF REPORTING PERSONS

     

    Lincoln Park Capital, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Illinois



    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    124,008

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    124,008

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    124,008

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.792%

    12

    TYPE OF REPORTING PERSON

     

    OO

     

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 293602207 Page 4 of 13

     

    1

    NAMES OF REPORTING PERSONS

     

    Rockledge Capital Corporation

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Texas



    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    124,008

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    124,008

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    124,008

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.792%

    12

    TYPE OF REPORTING PERSON

     

    CO

      

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 293602207 Page 5 of 13

     

    1

    NAMES OF REPORTING PERSONS

     

    Joshua B. Scheinfeld

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States



    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    124,008

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    124,008

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    124,008

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.792%

    12

    TYPE OF REPORTING PERSON

     

    IN

     

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 293602207 Page 6 of 13

     

    1

    NAMES OF REPORTING PERSONS

     

    Alex Noah Investors, Inc.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Illinois



    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    124,008

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    124,008

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    124,008

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.792%

    12

    TYPE OF REPORTING PERSON

     

    CO

     

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 293602207 Page 7 of 13

     

    1

    NAMES OF REPORTING PERSONS

     

    Jonathan I. Cope

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States



    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    124,008

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    124,008

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    124,008

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.792%

    12

    TYPE OF REPORTING PERSON

     

    IN

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 293602207 Page 8 of 13

     

    Item 1.  
       
      (a) Name of Issuer:
         
        Ensysce Biosciences, Inc., a Delaware corporation (the “Issuer”)
         
      (b) Address of Issuer’s Principal Executive Offices:
         
        7946 Ivanhoe Avenue, Suite 201
        La Jolla, California
         
    Item 2.  
       
      (a) Name of Person Filing:
         
        Lincoln Park Capital Fund, LLC (“LPC Fund”)
        Lincoln Park Capital, LLC (“LPC”)
        Rockledge Capital Corporation (“RCC”)
        Joshua B. Scheinfeld (“Mr. Scheinfeld”)
        Alex Noah Investors, Inc. (“Alex Noah”)
        Jonathan I. Cope (“Mr. Cope” and, collectively with LPC Fund, LPC, RCC, Mr. Scheinfeld and Alex Noah, the “Reporting Persons”)
         
      (b) Address of Principal Business Office, or if None, Residence:
         
        The address of the principal business office of each of the Reporting Persons is:
        440 North Wells, Suite 410
        Chicago, Illinois 60654
         
      (c) Citizenship:
         
        LPC Fund is an Illinois limited liability company
        LPC is an Illinois limited liability company
        RCC is a Texas corporation
        Mr. Scheinfeld is a United States citizen
        Alex Noah is an Illinois corporation
        Mr. Cope is a United States citizen

     

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 293602207 Page 9 of 13

     

      (d) Title of Class of Securities:
         
        Common Stock, par value $0.0001 per share (“Common Stock”)
         
      (e) CUSIP Number:
         
        293602207

     

    Item 3.

     

    If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f) ¨ An employee benefit plan or endowment fund in accordance with §240. 13d-1(b)(1)(ii)(F);
    (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
    (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).
         
    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution ______________________

     

     

     

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 293602207 Page 10 of 13

     

    Item 4.  Ownership.

     

    Reporting person   Amount
    beneficially
    owned1:
      Percent
    of class2:
      Sole power
    to vote or
    direct
    the vote:
      Shared power
    to vote or
    to direct
    the vote:
      Sole power
    to dispose or to
    direct the
    disposition of:
      Shared power
    to dispose or to
    direct the
    disposition of:
    Lincoln Park Capital Fund, LLC   124,008   3.792%   0   124,008   0   124,008
    Lincoln Park Capital, LLC   124,008   3.792%   0   124,008   0   124,008
    Rockledge Capital Corporation   124,008   3.792%   0   124,008   0   124,008
    Joshua B. Scheinfeld   124,008   3.792%   0   124,008   0   124,008
    Alex Noah Investors, Inc.   124,008   3.792%   0   124,008   0   124,008
    Jonathan I. Cope   124,008   3.792%   0   124,008   0   124,008

     

    1 Represents a warrant to purchase 124,008 shares of Common Stock (the “Warrant”) purchased by LPC Fund directly from the Issuer. The Warrant is exercisable at $8.58 per share and expires on August 7, 2028.

    2 As of December 31, 2023, LPC Fund beneficially owned 124,008 shares currently exercisable under the Warrant purchased directly from the Issuer. Based on the information contained in the Issuer’s Prospectus on Form S-1/A, filed with the Securities and Exchange Commission on November 17, 2023, there was a total of 3,146,139 shares of common stock outstanding as of November 17, 2023, which does not include the shares issuable upon exercise of the Warrant issued to LPC Fund. The percentage is calculated as of November 17, 2023, and assumes that all of the shares of Common Stock currently underlying the Warrant were issued and outstanding as of December 31, 2023.

     

    LPC is the Managing Member of LPC Fund. RCC and Alex Noah are the Managing Members of LPC. Mr. Scheinfeld is the president and sole shareholder of RCC, as well as a principal of LPC. Mr. Cope is the president and sole shareholder of Alex Noah, as well as a principal of LPC. As a result of the foregoing, Mr. Scheinfeld and Mr. Cope have shared voting and shared investment power over the shares of Common Stock of the Issuer held directly by LPC Fund.

     

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 293602207 Page 11 of 13

     

    Pursuant to Section 13(d) of the Act and the rules thereunder, each of LPC, RCC, Mr. Scheinfeld, Alex Noah, and Mr. Cope may be deemed to be a beneficial owner of the shares of Common Stock of the Issuer beneficially owned directly by LPC Fund.

     

    The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another Reporting Person. Pursuant to Rule 13d-4 of the Act, each of LPC, RCC, Mr. Scheinfeld, Alex Noah, and Mr. Cope disclaims beneficial ownership of the shares of Common Stock of the Issuer held directly by LPC Fund.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 293602207 Page 12 of 13

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

    LINCOLN PARK CAPITAL FUND, LLC   LINCOLN PARK CAPITAL, LLC
         
    BY: LINCOLN PARK CAPITAL, LLC   BY: ROCKLEDGE CAPITAL CORPORATION
         
    BY: ROCKLEDGE CAPITAL CORPORATION    
           
         
    By: /s/ Joshua B. Scheinfeld   By: /s/ Joshua B. Scheinfeld
      Name: Joshua B. Scheinfeld     Name: Joshua B. Scheinfeld
      Title: President     Title: President
         
    LINCOLN PARK CAPITAL FUND, LLC   LINCOLN PARK CAPITAL, LLC
         
    BY: LINCOLN PARK CAPITAL, LLC   BY: ALEX NOAH INVESTORS, INC.
         
    BY: ALEX NOAH INVESTORS, INC.    
           
         
    By: /s/ Jonathan I. Cope   By: /s/ Jonathan I. Cope
      Name: Jonathan I. Cope     Name: Jonathan I. Cope
      Title: President     Title: President
         
    ROCKLEDGE CAPITAL CORPORATION   ALEX NOAH INVESTORS, INC.
         
         
    By: /s/ Joshua B. Scheinfeld   By: /s/ Jonathan I. Cope
      Name: Joshua B. Scheinfeld     Name: Jonathan I. Cope
      Title: President     Title: President
         
    JOSHUA B. SCHEINFELD   JONATHAN I. COPE
         
         
    By: /s/ Joshua B. Scheinfeld   By: /s/ Jonathan I. Cope
      Name: Joshua B. Scheinfeld     Name: Jonathan I. Cope
      Title: President     Title: President

      

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 293602207 Page 13 of 13

     

    LIST OF EXHIBITS

     

    Exhibit No. Description
       
    99.1 Joint Filing Agreement

     

     

     

    Get the next $ENSC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ENSC

    DatePrice TargetRatingAnalyst
    11/30/2021$4.00Buy
    Lake Street
    More analyst ratings

    $ENSC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

      New York, NY, March 13, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce Biosciences, Inc. (NASDAQ:ENSC). The update note includes information on Ensysce Biosciences' business model, services, industry, financial results, valuation, and risks. The update note is available below. Ensysce March 2025 Update Note    Highlights from the note include:                                               Ensysce Biosciences Advances Strategic Initiatives and Clinical Programs: Ensysce Biosciences reported robust operational advancements for the fiscal year ended December 31

      3/13/25 8:00:00 AM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

      NEW YORK, March 3, 2025 /PRNewswire/ -- Today's Marketplace (TMP) is proud to announce a featured interview with Ensysce Biosciences (NASDAQ:ENSC) CEO Dr. Lynn Kirkpatrick and Dr. Neel Pathak, DS, Program Director with Creighton University. The doctors joined TMP's host Jane King to discuss the ongoing issues with opioids for pain management and how "clever chemistry" is being used to introduce safer opioids that are less prone to accidental overdose and abuse. "Our team uses what I like to call 'clever chemistry' to create the next generation of opioids."The full interview can be viewed online here. "[Unfortunately,] opioids are still being prescribed for pain

      3/3/25 9:43:00 AM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

      ~ Positive Phase 1b Data Confirms Overdose Protection for Highest Dosage Form of PF614-MPAR ~ SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced interim data from its second clinical trial to evaluate PF614-MPAR for overdose protection. Clinical study PF614-MPAR-102, ‘A Single and Multiple Dose Study to Evaluate the Pharmacokinetics of Oxycodone and PF614 when PF614 Capsule is Co‑Administered with Nafamostat as a Combination of Immediate Release Solutio

      1/22/25 8:00:00 AM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENSC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Gower Bob G bought $182,350 worth of shares (379,300 units at $0.48), increasing direct ownership by 50% to 1,132,395 units

      4 - Ensysce Biosciences, Inc. (0001716947) (Issuer)

      3/2/23 3:45:52 PM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Gower Bob G bought $500,000 worth of shares (357,143 units at $1.40), increasing direct ownership by 90% to 753,095 units

      4 - Ensysce Biosciences, Inc. (0001716947) (Issuer)

      2/1/23 6:06:45 PM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chang William H

      4 - Ensysce Biosciences, Inc. (0001716947) (Issuer)

      6/27/22 5:47:22 PM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENSC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on Ensysce Biosciences with a new price target

      Lake Street initiated coverage of Ensysce Biosciences with a rating of Buy and set a new price target of $4.00

      11/30/21 10:47:43 AM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENSC
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Ensysce Biosciences Inc.

      SCHEDULE 13G/A - Ensysce Biosciences, Inc. (0001716947) (Subject)

      5/15/25 4:30:09 PM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Ensysce Biosciences Inc.

      10-Q - Ensysce Biosciences, Inc. (0001716947) (Filer)

      5/13/25 4:20:32 PM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ensysce Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)

      5/13/25 4:15:12 PM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENSC
    Leadership Updates

    Live Leadership Updates

    See more
    • Ensysce Biosciences Announces Appointment of Dr. Nily Osman as Chief Medical Officer

      SAN DIEGO, CA / ACCESSWIRE / April 18, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a current focus on reducing abuse and overdose, today announced the appointment of Dr. Nily Osman as Chief Medical Officer effective April 18, 2022. Dr. Osman will succeed Dr. William Schmidt as he transitions to Senior VP of Clinical Development and continues his role on the Company's clinical advisory board.Dr. Osman, a highly versatile board-certified neurologist, migraine and pain specialist, has over ten years of experience in both R&D and

      4/18/22 4:05:00 PM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ensysce Biosciences Appoints Industry Veteran Lee Rauch to Board of Directors

      SAN DIEGO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a focus on reducing abuse and overdose while providing relief for those with severe pain, today announced that Lee Rauch has been appointed to the Company's board of directors. Ms. Rauch, an experienced Chief Executive Officer and Strategy Advisor, has served both public and private companies. During her near 40-year career, Ms. Rauch successful built companies ranging in focus from pre-clinical research to advanced clinical development, took

      2/8/22 4:01:00 PM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ensysce Biosciences Grows its Management Team with Appointment of Dr. Linda Pestano as Chief Development Officer

      SAN DIEGO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, has appointed Linda Pestano, PhD, Chief Development Officer effective October 15, 2021. Dr. Pestano has worked through her career to guide the development of novel therapeutics to improve patient outcomes and quality of life. Dr. Pestano received her PhD from Tuffs University and undertook a Post-Doctoral Fellowship with Dana Farber Cancer Institute at the Harvard Medical School in Boston. Her early research was vi

      10/26/21 8:00:00 AM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENSC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Ensysce Biosciences Inc.

      SC 13G - Ensysce Biosciences, Inc. (0001716947) (Subject)

      11/14/24 5:52:56 PM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ensysce Biosciences Inc.

      SC 13G - Ensysce Biosciences, Inc. (0001716947) (Subject)

      11/6/24 4:15:58 PM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ensysce Biosciences Inc.

      SC 13G - Ensysce Biosciences, Inc. (0001716947) (Subject)

      10/29/24 5:27:56 PM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENSC
    Financials

    Live finance-specific insights

    See more
    • Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

      Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation and Phase 3 Clinical PlansSAN DIEGO, CA / ACCESSWIRE / March 15, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the fourth quarter and full year of 2023.Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "We are proud of the significant progress Ensysce has made in 2023 both operationally and clinically for our lead pain therapeutic, PF614, and our overdose protection product, PF614-MPAR.

      3/15/24 8:00:00 AM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ensysce Biosciences Announces Updated Investor Presentation Available Via Investor Relations Website

      ~ Reminder: Corporate Update Conference Call to be Held Today at 11:00am ET ~SAN DIEGO, CA / ACCESSWIRE / April 11, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today announced an updated investor presentation has been posted to the Company's investor relations website. As a reminder, the Company will be holding a corporate update conference call today, Tuesday, April 11, 2023, at 11:00am ET.Corporate Update Conference CallDate: Tuesday, April 11, 2023Time: 11:00am ETU.S. Dial-in: 1-877-407-0792International Dial-in: 1-201-689-8263Webcast: ENSC Corporate Upd

      4/11/23 8:10:00 AM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock

      SAN DIEGO, CA / ACCESSWIRE / February 1, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that its Board of Directors has declared a dividend of 0.001 of a share of newly-designated Series A Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on February 13, 2023. The outstanding shares of Series A Preferred Stock will vote together with the outstanding shares of the Company's common stock, as a single class, excl

      2/1/23 8:05:00 AM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care